Back to top
more

ALX Oncology Holdings (ALXO)

(Real Time Quote from BATS)

$1.49 USD

1.49
381,061

+0.04 (2.76%)

Updated Nov 11, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

by Zacks Equity Research

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

by Zacks Equity Research

Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

by Zacks Equity Research

Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

by Zacks Equity Research

Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

by Zacks Equity Research

Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo

by Zacks Equity Research

Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

by Zacks Equity Research

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

by Zacks Equity Research

Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.

Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study

by Zacks Equity Research

Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

by Zacks Equity Research

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for ALX Oncology Holdings (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

by Zacks Equity Research

Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

by Zacks Equity Research

Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

by Zacks Equity Research

Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

by Zacks Equity Research

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

by Zacks Equity Research

Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

by Zacks Equity Research

Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

by Zacks Equity Research

Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.

Novartis (NVS) Presents Positive Data on Renal Drugs at ERA

by Zacks Equity Research

Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

by Zacks Equity Research

Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

by Zacks Equity Research

Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.

Regeneron (REGN) Announces Positive Data on Oncology Candidate

by Zacks Equity Research

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

by Zacks Equity Research

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why

by Zacks Equity Research

Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.